PepGen Inc. (PEPG)
Health Care · Oligonucleotide therapeutics · NASDAQ
PepGen is a biotechnology company developing novel oligonucleotide therapies that use proprietary peptide-based delivery technology to treat severe neuromuscular and neurological diseases.
What PepGen Inc. does
PepGen Inc. is a clinical-stage biotechnology company developing advanced oligonucleotide therapies for severe neuromuscular and neurological diseases. The company has developed a proprietary Enhanced Delivery Oligonucleotide (EDO) platform that leverages cell-penetrating peptides (CPPs) to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its lead candidate, PGN-EDODM1, is in clinical development for the treatment of myotonic dystrophy type 1 (DM1), with Phase 1 and Phase 2 trials underway across multiple geographies.
Themes: Oligonucleotide therapies, Rare genetic neuromuscular diseases, Myotonic dystrophy, Clinical-stage biotechnology, Drug delivery optimization
Fundamentals
- Price$3.22 as of 2026-08-26 close
- Market cap$223M as of 2026-08-26
- 1-year return+153.5% 2025-08-26 close $1.27 → 2026-08-26 close $3.22
- P/En/a earnings data not available
- ROE-51.0% as of 2026-08-27
- Debt / equity0.00 as of 2026-08-27
- Beta1.97 as of 2026-08-27
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How PEPG compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-27
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PepGen Inc. looks technically
PepGen Inc. (PEPG) is trading 15.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 78 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 50, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 2 trading days ago. It is 58.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 15.1% below its 200-day average, the long-term trend line — a long-term downtrend | -15.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.27 | $2.27 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.79 | $3.79 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 2.62. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 78 trading days ago — a "death cross", a bearish long-term signal | 78 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 50, with buyers in control | 50.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30) | 67.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($2.44 to $3.57) — its "stochastic" reading is 69 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 69.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.80 | $7.80 |
|---|---|---|
| From the 52-week high | it is 58.7% below its 52-week high (its highest price of the past year) | -58.7% |
| Above the 52-week low | it is 185.0% above its 52-week low (its lowest price of the past year) | +185.0% |
| Below the 52-week high | it is 58.7% below its highest point of the past year | 58.7% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $20.00 (set on 2023-03-24) | $20.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.16 to $7.17), and it has given back well over two thirds of its rise from last year’s low — 66% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.26 to $3.46. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 65.7% |
| From the all-time high | it is 83.9% below its all-time high | -83.9% |
| Nearest price level | it is trading 35.4% below a resistance level at $4.36 — a price it turned at twice since 2025-10-14, most recently on 2025-10-22. Since 2024-08-26 it has 4 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +35.4% |
| All-time low | its lowest closing price on record is $0.88 (set on 2025-04-09) | $0.88 |
| Above the all-time low | it is 265.9% above its all-time low | +265.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 77% of it) | 77th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2218 between its high and its low — about 6.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2218 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.66 and $3.77 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.66 – $2.72 – $3.77 |
| Typical daily range (% of price) | its price moves about 6.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.9% |
| Stretch from the 200-day average | it is trading 2.6 daily ranges below its 200-day average price (15.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.96× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-26 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.4% |
|---|---|---|
| Open gap | it gapped 2.9% above the previous close 13 sessions ago and has not traded back through the level it left behind at 2.41 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.9% |
| Gap filled | a 2.4% gap up opened on 2026-08-19 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 63.2 percentage points (the stock gained 66.8% while the market gained 3.7%) | +63.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 108.4 percentage points (the stock gained 110.5% while the market gained 2.1%) | +108.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 59.5 percentage points (the stock lost 48.4% while the market gained 11.1%) | -59.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 134.8 percentage points (the stock gained 153.5% while the market gained 18.7%) | +134.8% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 49% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.5% of the share price. | +48.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $2.92 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +10.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $2.87 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +12.2% |
Price levels it has turned at before
PEPG last closed at $3.22 on 2026-08-26. Since 2024-08-26 it has turned at 4 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.36 | Resistance | 35.4% above the last close | turned there twice · 2025-10-14 to 2025-10-22 |
| $4.49 | Resistance | 39.3% above the last close | turned there three times · 2024-12-27 to 2026-03-20 |
| $1.68 | Support | 47.8% below the last close | turned there twice · 2025-05-19 to 2026-07-30 |
| $1.61 | Support | 49.8% below the last close | turned there twice · 2025-06-09 to 2026-06-26 |
| $5.04 | Resistance | 56.6% above the last close | turned there three times · 2025-12-08 to 2026-03-05 |
| $1.35 | Support | 57.9% below the last close | turned there twice · 2025-06-03 to 2025-08-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $2.62.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $2.62 and $2.80 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 6 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.38 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$10.19 range $2.50 – $20.00; median $10.50
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PEPG
- Consensus EPS estimate-$0.2667 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["PGN-EDODM1 Phase 2 study remains on partial clinical hold in the U.S. pending FDA resolution of safety/efficacy questions, creating regulatory and development timeline uncertainty.","As a clinical-stage company with no approved products, PepGen has no revenue and requires substantial capital to fund ongoing clinical trials and future development, with significant financing risk if capital markets close or funding becomes unavailable.","Success depends on demonstrating sufficient efficacy and safety of PGN-EDODM1 in Phase 2 trials; failure to meet primary endpoints or unexpected adverse events could halt development and eliminate the company's primary asset."]
What changed in the latest 10-Q
AI-assisted comparison of PEPG's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-12) adds description of FREEDOM-OLE as an open label extension study for eligible participants who completed FREEDOM or FREEDOM2 studies
- Newer filing (2026-05-12) adds that FREEDOM study data was announced in 2025 with specific splicing correction percentages (12.3%, 29.1%, 53.7%)
- Newer filing (2026-05-12) adds that FREEDOM2 has received regulatory clearance in Canada, U.K., South Korea, Australia, and New Zealand
- Newer filing (2026-05-12) adds that FREEDOM2 remains on partial clinical hold in the U.S. and FDA questions are being addressed
- Newer filing (2026-05-12) adds topline results from FREEDOM2 5 mg/kg cohort with specific safety data (no SAEs, all related TEAEs mild, no cumulative toxicity)
- Newer filing (2026-05-12) adds discussion of outlier patient in FREEDOM2 affecting splicing correction mean (7.3% overall vs. 22.9% excluding outlier)
- Newer filing (2026-05-12) adds information on middle finger vHOT showing positive trend in treatment group versus worsening in placebo group
- Newer filing (2026-05-12) adds that FREEDOM2 is currently dosing 10 mg/kg cohort with data expected in second half of 2026
- Newer filing (2026-05-12) adds that EMA granted orphan medicinal product designation to PGN-EDODM1
- Newer filing (2026-05-12) adds that during three months ended March 31, 2026, 237,500 shares were sold under ATM program for net proceeds of $1.5 million
- Removed:
- Older filing (2025-11-12) includes 'Business Update' section header which is removed in newer filing
- Older filing (2025-11-12) states clinical development program includes two studies; newer filing (2026-05-12) states three studies (adds FREEDOM-OLE)
- Older filing (2025-11-12) states FREEDOM study is currently enrolling; newer filing (2026-05-12) states data was announced in 2025
- Older filing (2025-11-12) states FREEDOM2 is 'currently open' in Canada and U.K.; newer filing (2026-05-12) states it 'has received regulatory clearance' in multiple jurisdictions and is 'currently enrolling'
- Older filing (2025-11-12) states FREEDOM2 'plan[s] to open' in U.S. subject to regulatory authorization; newer filing (2026-05-12) states it 'remains on partial clinical hold in the U.S.'
- Older filing (2025-11-12) states all 5 mg/kg cohort participants have been enrolled with data expected in Q1 2026; newer filing (2026-05-12) reports topline results from 5 mg/kg cohort already released
- Older filing (2025-11-12) includes paragraph describing discontinuation of PGN-EDO51 development and winding down of DMD-related activities; this is completely removed in newer filing
- Older filing (2025-11-12) uses phrase 'shares of common stock shares' (with duplication); newer filing (2026-05-12) corrects to 'shares of common stock'
- Older filing (2025-11-12) states estimated offering expenses; newer filing (2026-05-12) states offering expenses without 'estimated'
- Reworded:
- Older filing (2025-11-12) states 'In the FREEDOM study, we are enrolling'; newer filing (2026-05-12) states 'In the FREEDOM study, we enrolled' (change from present to past tense)
- Older filing (2025-11-12) reports data announcement on February 24 and September 24, 2025; newer filing (2026-05-12) consolidates as 'announced data...in 2025'
- Older filing (2025-11-12) states 'we have decided to conclude dose escalation'; newer filing (2026-05-12) removes this statement and instead discusses ongoing dosing of 10 mg/kg cohort
- Notes:
- The newer filing text appears truncated at the end ('establishing and mai'), potentially affecting completeness of comparison in final paragraph
- Some changes reflect reporting of completed events (FREEDOM study results) versus ongoing enrollment status in older filing
Risk Factors
- Added:
- Added new risk factor 'We are substantially dependent on the success of our lead product candidate, PGN-EDODM1' as the first substantive risk factor in the 2026-05-12 filing
- Added specific language about 'partial clinical hold placed on the FREEDOM2 study' and need for 'successful outcome of discussions with the U.S. Food and Drug Administration' in 2026-05-12 filing
- Added reference to obtaining 'clearance to initiate sites in additional jurisdictions (such as the US)' as potential delay factor in 2026-05-12 filing
- Added phrase 'or other CMC activities which support registration, particularly as we scale for an anticipate Phase 3 pivotal trial and look to secure secondary source suppliers for our drug substance' in 2026-05-12 filing
- Removed:
- Removed 'manufacturing' from the list of resource allocation activities in the older filing; newer filing specifies this separately
- Removed statement 'We are still in the early stages of development of our programs and have only advanced two product candidates into clinical development' from 2025-11-12 filing
- Removed statement 'We announced in May 2025 that we are focusing our efforts on the development of PGN-EDODM1 and have voluntarily discontinued development of PGN-EDO51' from 2025-11-12 filing
- Removed bullet point about 'obtain, expand, maintain, defend and enforce our intellectual property portfolio' as separate item from 2025-11-12 filing
- Removed bullet point 'hire additional clinical, regulatory and scientific personnel' from 2025-11-12 filing
- Removed bullet point 'ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval' from 2025-11-12 filing
- Removed bullet point 'add operational, legal, compliance, financial and management information systems and personnel to support our research, product development and future commercialization efforts, as well as to support our operations as a public company' from 2025-11-12 filing
- Removed entire separate risk factor 'We have never generated revenue from product sales and may never achieve or maintain profitability' that appeared in 2025-11-12 filing
- Reworded:
- Changed financial metrics from 'nine months ended September 30, 2025 and September 30, 2024' with net losses of '$71.3 million and $67.7 million' and accumulated deficit of '$342.8 million' in older filing to 'three months ended March 31, 2026 and March 31, 2025' with net losses of '$17.8 million and $30.2 million' and accumulated deficit of '$378.9 million' in newer filing
- Changed description from 'currently only have one product candidate advancing into clinical development' (older) to removed statement about number of candidates (newer)
- Expanded bullet point on manufacturing from 'establish manufacturing sources for your product candidates and secure supply chain capacity to provide sufficient quantities for preclinical and clinical development and commercial supply' (2025-11-12) to include 'and other CMC activities which support registration, particularly as we scale for an anticipate Phase 3 pivotal trial and look to secure secondary source suppliers for our drug substance' (2026-05-12)
- Modified enrollment concern from 'including if enrollment for the FREEDOM2 study takes longer than anticipated' (2025-11-12) to 'including if enrollment for the FREEDOM2 study takes longer than anticipated or if we are unable to obtain clearance to initiate sites in additional jurisdictions (such as the US)' (2026-05-12)
- Added new bullet point 'address any new safety or efficacy concerns which may arise as we analyze interim, top-line, or preliminary data from the ongoing FREEDOM2 clinical trial, or other planned or future clinical trials' in 2026-05-12 filing
- Notes:
- The newer filing appears to be truncated mid-sentence ('seek marketing approvals for any') and may not contain the complete risk factors section
- Comparison is between a 10-Q for period ended March 31, 2026 (newer) and a 10-Q for period ended September 30, 2025 (older), representing different reporting periods which may naturally account for some content changes
- The older filing's section appears similarly truncated at the end, making complete structural comparison impossible for later portions
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 7 sells ($59312) — 4 selling insiders
Most recent open-market transaction: 2026-05-21. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PEPG's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding PEPG as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 5,411,794
- Reported value $9,578,874
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PEPG had 4,106,633 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PEPG had 5.93% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.1 days to cover at the same settlement.
- Reported short interest (shares) 4,106,633
- Short interest (% of shares outstanding) 5.93%
- Prior settlement (shares) 4,533,674
- Reported change -9.42%
- Days to cover (reported) 6.1
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sarepta Therapeutics (SRPT)
- Wave Life Sciences (WVE)
- Avidity Biosciences (RNA)
- Ionis Pharmaceuticals (IONS)
- Dyaiomics (DYN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PEPG vs…
PEPG ranks in…
Frequently asked questions
What does PepGen Inc. (PEPG) do?
PepGen Inc. is a clinical-stage biotechnology company developing advanced oligonucleotide therapies for severe neuromuscular and neurological diseases. The company has developed a proprietary Enhanced Delivery Oligonucleotide (EDO) platform that leverages cell-penetrating peptides (CPPs) to improve the uptake and activity of conjugated oligonucleotide therapeutics.
What sector is PepGen Inc. (PEPG) in?
PepGen Inc. (PEPG) is classified in the Health Care sector. Its industry is Oligonucleotide therapeutics. It trades on NASDAQ.
Who are PepGen Inc.'s (PEPG) competitors?
Notable peers of PepGen Inc. (PEPG) include Sarepta Therapeutics, Wave Life Sciences, Avidity Biosciences, Ionis Pharmaceuticals and Dyaiomics. This peer set is informational only — not financial advice.
Is PepGen Inc. (PEPG) overbought or oversold right now?
PepGen Inc. (PEPG) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 68, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PEPG come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.